William Seaman, MD

Professor

Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
MD, 1969 - Medicine, Harvard Medical School
Websites
Publications
  1. Georgia Abortion Law and our Commitment to Patients.
  2. New blood: Creative funding of disease-specific research.
  3. Traumatic brain injury induces macrophage subsets in the brain.
  4. Iron uptake mediated by binding of H-ferritin to the TIM-2 receptor in mouse cells.
  5. Synergistic Ca2+ responses by G{alpha}i- and G{alpha}q-coupled G-protein-coupled receptors require a single PLC{beta} isoform that is sensitive to both G{beta}{gamma} and G{alpha}q.
  6. Clostridium difficile toxin B differentially affects GPCR-stimulated Ca2+ responses in macrophages: independent roles for Rho and PLA2.
  7. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1.
  8. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia.
  9. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria.
  10. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria.
  11. Tim-2 is the receptor for H-ferritin on oligodendrocytes.
  12. Signaling and cross-talk by C5a and UDP in macrophages selectively use PLCbeta3 to regulate intracellular free calcium.
  13. The innate immune response to Salmonella enterica serovar Typhimurium by macrophages is dependent on TREM2-DAP12.
  14. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression.
  15. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12.
  16. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function.
  17. Clinical academic rheumatology: comment on the article by Wickersham et al.
  18. TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis.
  19. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands.
  20. Expression and activation of signal regulatory protein alpha on astrocytomas.
  21. CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation.
  22. Pattern recognition by TREM-2: binding of anionic ligands.
  23. Overview of the Alliance for Cellular Signaling.
  24. Characterization of TREM-3, an activating receptor on mouse macrophages: definition of a family of single Ig domain receptors on mouse chromosome 17.
  25. Ligand interactions by activating and inhibitory Ly-49 receptors.
  26. Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family.
  27. Activating Ly-49D and inhibitory Ly-49A natural killer cell receptors demonstrate distinct requirements for interaction with H2-D(d).
  28. Natural killer cells and natural killer T cells.
  29. Natural killing of xenogeneic cells mediated by the mouse Ly-49D receptor.
  30. Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity.
  31. DAP12-mediated signal transduction in natural killer cells. A dominant role for the Syk protein-tyrosine kinase.
  32. The alpha2 domain of H-2Dd restricts the allelic specificity of the murine NK cell inhibitory receptor Ly-49A.
  33. Natural killer cells and recognition of MHC class I molecules: new perspectives and challenges in immunology.
  34. Mouse Ly-49A interrupts early signaling events in natural killer cell cytotoxicity and functionally associates with the SHP-1 tyrosine phosphatase.
  35. Divergent functions of lectin-like receptors on NK cells.
  36. Recognition and Signaling by Mouse Ly-49 Receptors.
  37. An autosomal dominant locus, Nka, mapping to the Ly-49 region of a rat natural killer (NK) gene complex, controls NK cell lysis of allogeneic lymphocytes.
  38. Recognition and signaling by mouse Ly-49 receptors.
  39. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity.
  40. A family of murine NK cell receptors specific for target cell MHC class I molecules.
  41. Ly-49A, a receptor for H-2Dd, has a functional carbohydrate recognition domain.
  42. A natural killer cell receptor specific for a major histocompatibility complex class I molecule.
  43. The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex.
  44. Molecular cloning of the NK1.1 antigen, a member of the NKR-P1 family of natural killer cell activation molecules.
  45. The OX-44 molecule couples to signaling pathways and is associated with CD2 on rat T lymphocytes and a natural killer cell line.
  46. NKR-P1, an activating molecule on rat natural killer cells, stimulates phosphoinositide turnover and a rise in intracellular calcium.
  47. cDNA cloning of mouse NKR-P1 and genetic linkage with LY-49. Identification of a natural killer cell gene complex on mouse chromosome 6.
  48. Divergent regulation of phospholipase C-alpha and phospholipase C-gamma transcripts during activation of a human T cell line.
  49. Characterization of signal-transducing molecules on natural killer cells.
  50. Molecular cloning of gp42, a cell-surface molecule that is selectively induced on rat natural killer cells by interleukin 2: glycolipid membrane anchoring and capacity for transmembrane signaling.
  51. Identification and characterization of a cell-surface molecule that is selectively induced on rat lymphokine-activated killer cells.
  52. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells.
  53. Receptor-specific mechanisms for the responses of human leukocytes to leukotrienes.
  54. Selective manipulation of the immune response in vivo by monoclonal antibodies.
  55. Randomized, double-blind, placebo-controlled study of the treatment of the painful shoulder.
  56. Regulation of autoimmunity and donor cell engraftment by recipient Lyt-2+ cells during the graft-versus-host reaction.
  57. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity.
  58. Inositol trisphosphate is generated by a rat natural killer cell tumor in response to target cells or to crosslinked monoclonal antibody OX-34: possible signaling role for the OX-34 determinant during activation by target cells.
  59. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
  60. In vivo effects of antilymphocyte antibodies on immunity and autoimmunity.
  61. Rejection of skin grafts and generation of cytotoxic T cells by mice depleted of L3T4+ cells.
  62. Induction of immune tolerance by administration of monoclonal antibody to L3T4.
  63. Cocaine increases natural killer cell activity.
  64. Analysis of the function of L3T4+ T cells by in vivo treatment with monoclonal antibody to L3T4.
  65. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice.
  66. Human synovial dendritic cells. Direct observation of transition to fibroblasts.
  67. Harvesting of leukocytes from intestinal lumen in murine giardiasis and preliminary characterization of these cells.
  68. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.
  69. Treatment of murine lupus with monoclonal anti-T cell antibody.
  70. THE POTENTIAL ROLE OF ARACHIDONIC ACID METABOLISM IN NATURAL KILLER CELL ACTIVITY11Supported by Public Health Service grants Nos. CA34529 and AI5384 and by the Veterans Administration.
  71. Human and murine natural killer cell activity may require lipoxygenation of arachidonic acid.
  72. The proliferating cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T cells that is involved in the response to class II major histocompatibility antigens.
  73. Monocytosis in the BXSB model for systemic lupus erythematosus.
  74. Human natural killer cell activity is reversibly inhibited by antagonists of lipoxygenation.
  75. Natural killing activity in Sjögren's syndrome. An analysis of defective mechanisms.
  76. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.
  77. Thymic influences on autoimmunity in MRL-lpr mice.
  78. Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes: requirement for reactive metabolites of oxygen.
  79. The Lyt-2, Lyt-3 macromolecules: structural and functional studies.
  80. Suppression or enhancement of natural killing does not alter tolerance to bovine gamma globulin.
  81. Surface antigens on mouse natural killer cells: use of monoclonal antibodies to inhibit or to enrich cytotoxic activity.
  82. Natural killing by spleen cells from W/Wv and Sl/Sld anemic mice.
  83. Lyt-2 and lyt-3 antigens are on two different polypeptide subunits linked by disulfide bonds. Relationship of subunits to T cell cytolytic activity.
  84. Natural killing of tumor cells by human peripheral blood cells. Suppression of killing in vitro by tumor-promoting phorbol diesters.
  85. Effect of 89Sr on immunity and autoimmunity in NZB/NZW F1 mice.
  86. THE EFFECT OF 17ß-ESTRADIOL ON NATURAL KILLING IN THE MOUSE.
  87. Natural killing in estrogen-treated mice responds poorly to poly I.C despite normal stimulation of circulating interferon.
  88. Effect of estrogen on natural killer cells.
  89. Natural killer cells, bone, and the bone marrow: studies in estrogen-treated mice and in congenitally osteopetrotic (mi/mi) mice.
  90. beta-Estradiol reduces natural killer cells in mice.
  91. Hepatic injury due to acetaminophen or salicylates.
  92. Letter: Effect of salicylates on creatinine clearance.
  93. Effect of aspirin on liver tests in patients with RA or SLE and in normal volunteers.
  94. Systemic lupus erythematosus. Contrasts and comparisons.
  95. Avascular necrosis of the talus, scaphoid, and metatarsal head in systemic lupus erythematosus.
  96. Proceedings: Aspirin-induced hepatotoxicity in patients with RA or systemic lupus erythematosus (SLE).
  97. Letter: Aspirin and hepatotoxicity: addendum.
  98. Aspirin-induced hepatotoxicity in patients with systemic lupus erythematosus.